TR200807263A2 - IgG'nin FcRn'ye bağlanmasını bloke eden peptidler - Google Patents

IgG'nin FcRn'ye bağlanmasını bloke eden peptidler

Info

Publication number
TR200807263A2
TR200807263A2 TR200807263A TR200807263A TR200807263A2 TR 200807263 A2 TR200807263 A2 TR 200807263A2 TR 200807263 A TR200807263 A TR 200807263A TR 200807263 A TR200807263 A TR 200807263A TR 200807263 A2 TR200807263 A2 TR 200807263A2
Authority
TR
Turkey
Prior art keywords
fcrn
peptides
igg binding
methods
blocking igg
Prior art date
Application number
TR200807263A
Other languages
English (en)
Original Assignee
Syntonix Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntonix Pharmaceuticals, Inc. filed Critical Syntonix Pharmaceuticals, Inc.
Publication of TR200807263A2 publication Critical patent/TR200807263A2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)

Abstract

Bu buluş insan FcRn'sine bağlanan ve bir IgG'nin Fc bölümünün FcRn'ye bağlanmasını inhibe eden, böylece serum IgG seviyelerini modüle eden peptidlerle ilgilidir. Açıklanan bileşimler ve usuller örneğin oto-bağışıklık hastalıklarının ve enflamatuvar hastalıkların tedavisinde kullanılabilir. Buluş ayrıca buluşa göre olan peptidleri kullanma ve usulleri ve hazırlama usulleri ile ilgilidir.
TR200807263A 2006-02-17 2007-02-16 IgG'nin FcRn'ye bağlanmasını bloke eden peptidler TR200807263A2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77485306P 2006-02-17 2006-02-17
US80563406P 2006-06-23 2006-06-23

Publications (1)

Publication Number Publication Date
TR200807263A2 true TR200807263A2 (tr) 2009-03-23

Family

ID=38291305

Family Applications (2)

Application Number Title Priority Date Filing Date
TR200807263A TR200807263A2 (tr) 2006-02-17 2007-02-16 IgG'nin FcRn'ye bağlanmasını bloke eden peptidler
TR200807263T TR200807263T1 (tr) 2006-02-17 2007-02-16 IgG'nin FcRn'ye bağlanmasını bloke eden peptidler

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR200807263T TR200807263T1 (tr) 2006-02-17 2007-02-16 IgG'nin FcRn'ye bağlanmasını bloke eden peptidler

Country Status (16)

Country Link
US (2) US8101186B2 (tr)
EP (1) EP1991572A2 (tr)
JP (1) JP2009527499A (tr)
KR (1) KR20080106432A (tr)
AU (1) AU2007217042A1 (tr)
BR (1) BRPI0707920A2 (tr)
CA (1) CA2638867A1 (tr)
EA (1) EA200870274A1 (tr)
IL (1) IL193101A0 (tr)
ME (1) MEP7408A (tr)
MX (1) MX2008010327A (tr)
NO (1) NO20083712L (tr)
RS (1) RS20080362A (tr)
TR (2) TR200807263A2 (tr)
TW (1) TW200745163A (tr)
WO (1) WO2007098420A2 (tr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2449918B1 (de) * 2003-04-22 2013-07-10 Trisa Holding AG Bürstenkopf für eine Elektrozahnbürste
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
MX2010001363A (es) * 2007-08-09 2010-03-09 Syntonix Pharmaceuticals Inc Peptidos inmunomoduladores.
WO2010014909A1 (en) * 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
JP2013511554A (ja) * 2009-11-23 2013-04-04 パラティン テクノロジーズ，インコーポレイテッド メラノコルチン−１受容体特異的線状ペプチド
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
CN104011207B (zh) 2011-10-31 2018-09-18 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
SG10201805584YA (en) 2012-02-24 2018-08-30 Chugai Pharmaceutical Co Ltd ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
ES2660912T3 (es) 2013-03-15 2018-03-26 Affibody Ab Nuevos polipéptidos
WO2014205072A2 (en) 2013-06-18 2014-12-24 The Brigham And Women's Hospital, Inc. FC RECEPTOR (FcRn) BINDING PEPTIDES AND USES THEREOF
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
CN112142843B (zh) 2013-12-24 2024-10-18 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
CN118440206A (zh) 2014-04-07 2024-08-06 中外制药株式会社 免疫活化抗原结合分子
EP3144388B1 (en) 2014-05-13 2020-07-01 Chugai Seiyaku Kabushiki Kaisha T cell-redirecting antigen-binding molecule for cells having immunosuppression function
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
SI3193930T1 (sl) 2014-09-17 2019-10-30 Affibody Ab Novi polipeptidi
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP6781712B2 (ja) * 2014-12-22 2020-11-04 コンシッリョ ナツィオナーレ デッレ リチェルケＣｏｎｓｉｇｌｉｏ Ｎａｚｉｏｎａｌｅ Ｄｅｌｌｅ Ｒｉｃｅｒｃｈｅ 心臓へ治療用／診断用化合物を送達するための生成物
MY188761A (en) 2015-03-09 2021-12-29 Argenx Bvba Method of reducing serum levels of fc-containing agents using fcrn antagonists
ES2945313T3 (es) 2015-04-17 2023-06-30 Amgen Res Munich Gmbh Construcciones de anticuerpos biespecificos para CDH3 y CD3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
EP3411404B1 (en) 2016-02-03 2022-11-09 Amgen Research (Munich) GmbH Psma and cd3 bispecific t cell engaging antibody constructs
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
CN106771251B (zh) * 2017-01-10 2019-03-15 柏荣诊断产品（上海）有限公司 兼顾特异性和灵敏度的免疫球蛋白G4亚型IgG4检测试剂盒
DK3661954T3 (da) 2017-08-03 2022-04-19 Amgen Inc Interleukin-21-muteiner og fremgangsmåder til behandling
MA50077A (fr) 2017-09-08 2020-07-15 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
CN107903302B (zh) * 2017-11-22 2021-05-14 韶远科技（上海)有限公司 一种γ-内酰胺桥联二肽类化合物的制备方法
CN111615517B (zh) * 2017-11-27 2024-01-09 香港大学 Yeats抑制剂及其使用方法
US12240875B2 (en) 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
CA3101462A1 (en) 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
JOP20210022A1 (ar) 2018-08-03 2021-01-28 Amgen Inc بنيات جسم مضاد لـ cldn18.2وcd3
WO2020227341A1 (en) * 2019-05-06 2020-11-12 9 Meters Biopharma, Inc. Compositions and methods for treating sjogren's syndrome
CN114126647A (zh) 2019-06-07 2022-03-01 阿尔金克斯有限公司 适用于皮下施用的FcRn抑制剂的药物制剂
CR20220049A (es) 2019-07-10 2022-03-02 Chugai Pharmaceutical Co Ltd Moléculas de unión a claudina-6 y usos de las mismas
EP3819007B1 (en) 2019-11-11 2024-07-10 Amgen Research (Munich) GmbH Dosing regimen for anti-bcma agents
EP4085144A4 (en) 2019-12-19 2024-03-27 The Trustees of The University of Pennsylvania COMPOSITIONS FOR THE TREATMENT OF FRIEDREICH AAXIA
BR112022013554A2 (pt) 2020-01-08 2022-09-06 argenx BV Métodos para tratar distúrbios do pênfigo
EP4093771A1 (en) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
IL325936A (en) * 2020-01-22 2026-03-01 Spark Therapeutics Inc Compositions and methods for enhancing or improving transduction of gene therapy vectors and removing or reducing immunoglobulins
WO2021183861A1 (en) 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
US20230220069A1 (en) 2020-06-17 2023-07-13 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of gene therapy patients
IL301926A (en) 2020-11-06 2023-06-01 Amgen Inc Antigen binding domain with reduced clipping rate
EP4240767A1 (en) 2020-11-06 2023-09-13 Amgen Inc. Polypeptide constructs binding to cd3
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
US20250136704A1 (en) 2020-11-10 2025-05-01 Amgen Inc. Methods for administering a bcmaxcd3 binding molecule
EP4274592A4 (en) * 2021-01-11 2025-03-19 The Trustees of The University of Pennsylvania COMPOSITIONS FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
US20240309065A1 (en) 2021-06-23 2024-09-19 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Short apoc-ii mimetic peptides and methods of use
WO2023109928A1 (zh) * 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体
US20250101104A1 (en) 2022-01-26 2025-03-27 Mabswitch Inc. Bispecific molecule with tunable affinity to a targeted antigen
IL316418A (en) 2022-05-05 2024-12-01 Us Health Short apolipoprotein E mimetic peptides and methods of use
CA3258000A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
WO2024200573A1 (en) 2023-03-27 2024-10-03 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
GB202318512D0 (en) * 2023-12-04 2024-01-17 argenx BV Methods of determining potency
US20260092096A1 (en) 2024-05-14 2026-04-02 35Pharma Inc. Activin receptor type iib variants and uses thereof
WO2026035730A1 (en) 2024-08-06 2026-02-12 Covant Therapeutics Operating, Inc. Cyclic peptide modulators of fcrn and uses thereof
WO2026055212A1 (en) 2024-09-03 2026-03-12 Covant Therapeutics Operating, Inc. Allosteric modulators of fcrn and uses thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5677440A (en) 1990-07-16 1997-10-14 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates
US5492821A (en) 1990-11-14 1996-02-20 Cargill, Inc. Stabilized polyacrylic saccharide protein conjugates
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
US5623053A (en) 1992-01-10 1997-04-22 California Institute Of Technology Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
US5449761A (en) 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
CN1214080A (zh) 1995-09-26 1999-04-14 华盛顿州大学 Rfhv/kshv亚族疱疹病毒的糖蛋白b
US7141676B1 (en) 1996-02-08 2006-11-28 University Of Washington Water soluble multi-biotin-containing compounds
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
US6214795B1 (en) * 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6128119A (en) 1997-01-10 2000-10-03 Asahi Kogaku Kogyo Kabushiki Kaisha Beam shaping optical system
US6472506B1 (en) 1997-01-21 2002-10-29 Aventis Pasteur S.A. Polysaccharide-peptide-conjugates
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7473528B2 (en) 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US20040241727A1 (en) 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of schizophrenia related gene transcripts in blood
US6469136B1 (en) 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
RU2269354C2 (ru) * 1999-09-28 2006-02-10 Байер Корпорейшн Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения
AU5943201A (en) 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
JP2002214374A (ja) 2001-01-15 2002-07-31 Agilent Technologies Japan Ltd 位置決め装置及び位置決め方法
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2004043403A2 (en) 2002-11-13 2004-05-27 The Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
WO2005035732A2 (en) 2003-02-19 2005-04-21 Dyax Corporation Papp-a ligands
CA2522690A1 (en) 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2004108885A2 (en) 2003-05-06 2004-12-16 Syntonix Pharmaceuticals, Inc. Fc chimeric proteins with anti-hiv drugs
JP2007501847A (ja) 2003-08-08 2007-02-01 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US7176185B2 (en) 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
CA2552788C (en) * 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
DE102004031579B4 (de) * 2004-06-29 2012-12-27 Forschungsverbund Berlin E.V. Peptide zur Inhibition der Interaktion von Proteinkinase A und Proteinkinase A-Ankerproteinen, diese umfassendes Nukleinsäuremolekül, Vektor, Wirtszelle, gegen diese gerichtetes Erkennungsmolekül, diese enthaltende pharmazeutische Zusammensetzung, diese enthaltender Kit und deren Verwendung
EP1877099B1 (en) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
MX2010001363A (es) 2007-08-09 2010-03-09 Syntonix Pharmaceuticals Inc Peptidos inmunomoduladores.
WO2010014909A1 (en) 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides

Also Published As

Publication number Publication date
WO2007098420A8 (en) 2009-09-11
IL193101A0 (en) 2009-02-11
KR20080106432A (ko) 2008-12-05
TR200807263T1 (tr) 2009-02-23
MX2008010327A (es) 2009-01-26
TW200745163A (en) 2007-12-16
JP2009527499A (ja) 2009-07-30
EA200870274A1 (ru) 2009-02-27
US20110059889A1 (en) 2011-03-10
US9012603B2 (en) 2015-04-21
AU2007217042A2 (en) 2009-04-23
CA2638867A1 (en) 2007-08-30
RS20080362A (sr) 2009-07-15
MEP7408A (xx) 2010-02-10
WO2007098420A3 (en) 2008-01-17
US20070254831A1 (en) 2007-11-01
EP1991572A2 (en) 2008-11-19
US8101186B2 (en) 2012-01-24
WO2007098420A2 (en) 2007-08-30
BRPI0707920A2 (pt) 2011-05-17
AU2007217042A1 (en) 2007-08-30
NO20083712L (no) 2008-10-20

Similar Documents

Publication Publication Date Title
TR200807263T1 (tr) IgG'nin FcRn'ye bağlanmasını bloke eden peptidler
MX2009008230A (es) Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
PH12014502184A1 (en) Anti-hla-b* 27 antibodies and uses thereof
BR112012007523A2 (pt) moléculas de anticorpo anti-gcc e composições e métodos relacionados
UA105760C2 (uk) Антитіло проти bst2
TW200801041A (en) Antibodies against human IL-22 and uses therefor
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
MX2010001363A (es) Peptidos inmunomoduladores.
MX2018005512A (es) Agentes de union de esclerostina.
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
WO2006118772A3 (en) Fcrn antibodies and uses thereof
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
TR201804897T4 (tr) Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
EA200701211A1 (ru) Полипептиды, которые связываются с br3, и их применение
PH12015500093A1 (en) Il-17 binding proteins
PH12014502419A1 (en) Specific binding proteins and uses thereof
EA201000844A1 (ru) Связывающие wise агенты и эпитопы
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
MX2008009886A (es) Anticuerpos que enlazan par-2.
MX348432B (es) Epitopes.
NO20085362L (no) Hoyaffinitets humane og humaniserte anti-alfa5 beta1-integrin funksjonsblokkerende antistoffer med redusert immunogenisitet
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
ATE500276T1 (de) Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
EA200970332A1 (ru) Новые антигены и антитела, ассоциированные с аденокарциномой панкреатического протока